Abstract
Liver cirrhosis is one of the top 10 causes of death worldwide, and liver disease is in the top five in many developing countries. The treatment of liver cirrhosis at various stages necessitates the development of new organ transplantation techniques. One of these options is cell therapy, which has lately been used to treat a wide range of illnesses. The study used a rabbit model of liver cirrhosis to examine the efficiency of mesenchymal stem cell (MSC) transplantation. Subcutaneous injections of carbon tetrachloride (CCL4) were used to cause liver cirrhosis. When liver cirrhosis developed, autologous mesenchymal stem cells were infused into the portal vein. The histological image of the cirrhotic liver improved one month after MSC transplantation. This demonstrates that the intraportal delivery of autologous MSC to rabbits with experimental liver cirrhosis has good therapeutic outcomes.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call